10 Best Gene Therapy Stocks to Buy in 2026
Gene therapies aim to treat or prevent diseases by introducing new instructions in a patient’s cells to fix or replace the defective genes behind genetic disorders.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 10,326,103 | $89,312,864 | 1.75% | |
| 2. | Rubric Capital Management David Rosen | 7,000,000 | $60,620,000 | +14% | 0.64% |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 4,000,000 | $34,640,000 | 0.05% | |
| 4. | Millennium Management Israel Englander | 3,465,699 | $30,012,953 | +10% | 0.01% |
| 5. | Prosight Capital Lawrence Hawkins | 2,629,971 | $22,775,549 | -19% | 3.73% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.00 | 1,250,000 | $5,000,000.00 | 12,531,103 | 2024-08-12 | Filing | |
| $5.75 | 4,347,826 | $24,999,999.50 | 11,281,103 | 2023-05-05 | Filing | |
| $7.89 | 6 | $47.34 | 5,000 | 2022-06-03 | Filing | |
| $7.90 | 4,994 | $39,452.60 | 4,994 | 2022-06-03 | Filing | |
| $7.94 | 1,000 | $7,940.00 | 1,000 | 2022-05-25 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.51 | 56,000 | $700,560.00 | 908,530 | 2026-07-21 | Filing | |
| $14.90 | 25,112 | $374,168.80 | 640,846 | 2026-07-07 | Filing | |
| $13.86 | 2,547 | $35,301.42 | 665,958 | 2026-07-07 | Filing | |
| $9.17 | 62,000 | $568,540.00 | 1,387,695 | 2026-05-19 | Filing | |
| $10.22 | 56,000 | $572,320.00 | 971,530 | 2026-04-21 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,197,737 | $164,791,427 | 30.86% | |
| 2. | 691,200 | $8,667,648 | 0.07% | |
| 3. | 421,979 | $5,700,936 | 0.16% | |
| 4. | 148,065 | $2,000,358 | 0.04% | |
| 5. | 93,186 | $1,258,943 | 0.01% |